title: [Treatment of 46 cases of renal pelvic and ureteral tumors].
abstract: During about 10 years from November, 1977 to March, 1987, 46 patients with renal pelvic and ureteral tumors were treated at the Department of Urology, Hamamatsu University School of Medicine and the affiliated hospitals. There were 34 males and 12 females with the highest age incidence in the seventies. Histologically, 44 transitional cell carcinomas and 2 squamous cell carcinomas were found. Of the 44 transitional cell carcinomas, 1 was Tis; 13 T1, 2 T2, 8 T3, 15 M+ (with metastatic lesion), and 5 TX. As to grading, 1 was G1; 24 G2, 15 G3, and 4 GX. Staging was correlated with grading. The 5-year survival rates (Kaplan-Meier's method) were 37% in patients with transitional cell carcinoma. Among patients with transitional cell carcinoma, the 5-year survival rate was 43% for G2 and 42% for G3. As to staging, the 5-year survival rates were 71% and 46% in patients with stage of T1 and T3, respectively. No patient with M+ survived longer than 4 years. The 5-year survival rates were 38% and 34% in renal pelvic tumors (24 cases) and ureteral tumors (20 cases), respectively. As to the treatments, the 5-year survival rates after curable treatment (24 cases) and non-curable treatment (20 cases) were 63% and 7%, respectively.
authors.forename: Y
authors.initials: Y
authors.lastname: Aso
authors.forename: T
authors.initials: T
authors.lastname: Ushiyama
authors.forename: A
authors.initials: A
authors.lastname: Tajima
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Ohtawara
authors.forename: N
authors.initials: N
authors.lastname: Ohta
authors.forename: Y
authors.initials: Y
authors.lastname: Ohmi
authors.forename: M
authors.initials: M
authors.lastname: Hata
authors.forename: H
authors.initials: H
authors.lastname: Masuda
authors.forename: T
authors.initials: T
authors.lastname: Kanbayashi
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000628:therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014516:Ureteral Neoplasms / Q000401:mortality / Q000628:therapy*